New combo therapy aims to fight Hard-to-Treat cancers
NCT ID NCT07390383
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called LBL-024 combined with other cancer drugs (capecitabine, tislelizumab, and oxaliplatin) in 110 adults with advanced solid tumors. The goal is to see if the combination shrinks tumors and is safe. Participants must be in good overall health and have a life expectancy of at least 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LBL-024 (an experimental drug) combined with capecitabine, tislelizumab, and oxaliplatin
- What this could lead to
- If successful, this could point toward a new combination treatment option for people with advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is an early Phase 2 trial with only 110 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOUR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Beijing GoBroad Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100070, China
-
Shandong Cancer Hospital
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
-
Shanxi Provincial Cancer Hospital
NOT_YET_RECRUITINGTaiyuan, Shanxi, 030013, China
-
The Affiliated Hospital of Qingdao University
NOT_YET_RECRUITINGQingdao, Shandong, 266000, China
-
The Fourth Hospital of Hebei Medical University
NOT_YET_RECRUITINGShijiazhuang, Hebei, 050000, China
-
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300202, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?